Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial
Hillel Panitch, Douglas Goodin, Gordon Francis, Peter Chang, Patricia Coyle, Paul O'Connor, David Li, Brian WeinshenkerVolume:
239
Year:
2005
Language:
english
DOI:
10.1016/j.jns.2005.08.003
File:
PDF, 153 KB
english, 2005